Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 199Terminated 83Unknown 78Recruiting 67Active not recruiting 29Not yet recruiting 26Withdrawn 24Suspended 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Peritoneal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 8Magnetic Resonance Spectroscopy 7Biopsy 5Nivolumab 4Capecitabine 4Vincristine 3Radiosurgery 3Paclitaxel 3Irinotecan 3Fluorouracil 3Everolimus 3Docetaxel 3Dexamethasone 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3trifluridine tipiracil drug combination 2spartalizumab 2pembrolizumab 2lenvatinib 2daratumumab 2Taxes 2Radiation 2Prednisone 2Pemetrexed 2Oxaliplatin 2Mitoxantrone 2Leucovorin 2Injections 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Suspended × Pemetrexed × Clear all
NCT03875144 2026-02-09

MESOTIP

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Suspended
66 enrolled
Gynecologic

Peritoneal Neoplasms

NCT01088620 2013-03-14

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2 Suspended
134 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡